Remove portfolio
article thumbnail

Mydecine Expands Portfolio of Novel Molecules Filing New Patent for MDMA-like Compounds

Cannabis Law Report

This filing is part of our continued efforts to grow our robust IP portfolio as we consistently file for new patents that offer high potential to expand psychedelics for medical use.”. The post Mydecine Expands Portfolio of Novel Molecules Filing New Patent for MDMA-like Compounds appeared first on CannabisFN.

article thumbnail

Sugarbud Expands Product Portfolio In Ontario

Cannabis Law Report

(TSXV: SUGR, SUGR.DB, SUGR.WR, SUGR.WS, SUGR.WT,) (OTCQB: SBUDF) (“Sugarbud” or the “Company”) is pleased to announce the expansion of the Company’s product portfolio in Ontario with the launch of Mule Fuel. The post Sugarbud Expands Product Portfolio In Ontario appeared first on CannabisFN.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Press Release: Origin Therapeutics Announces First Five Portfolio Companies

Cannabis Law Report

Origin Therapeutics, an actively managed investment issuer focused on making equity investments in psychedelics-related companies, has filed its prospectus with plans to go public, and has announced its first five portfolio companies: Microdose Psychedelic Insights aims to unlock the potential of psychedelics through Industry events, market intelligence, (..)

article thumbnail

Press Release: CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings

Cannabis Law Report

Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications. The post Press Release: CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings first appeared on Cannabis Law Report.

Access 98
article thumbnail

Press Release: Origin Therapeutics Portfolio Company Tripsitter Expands to Eight Additional States

Cannabis Law Report

(CSE: ORIG Proposed) (the “Company” or “Origin Therapeutics”) an actively managed investment issuer focused on making equity investments in psychedelics-related companies, is announcing that its portfolio company Tripsitter Clinic Corp. The Company manages investments via advisory support roles to help boost portfolio company growth.

Therapy 95
article thumbnail

Nextleaf Focused on Owning The Largest Patent Portfolio for the Extraction, Distillation, and Delivery of Cannabinoids

Cannabis Law Report

This announcement became one of over 80 patents held by the company, and makes it the third-largest portfolio of U.S. The company’s overall vision is to improve cannabis oil economics globally by owning the largest globally protected patent portfolio within cannabis processing technology. cannabis patents to date.

article thumbnail

CB Therapeutics Expands Biomanufacturing IP Portfolio

Cannabis Law Report

CB Therapeutics has been awarded two additional patents for its breakthrough biosynthesis platform. These patents cover new cellular agriculture advances for producing high value compounds.